论文部分内容阅读
目的研究艾司西酞普兰对慢性阻塞性肺疾病(COPD)患者抑郁焦虑症状疗效及安全性,并评价患者用药前后的生活质量。方法采用汉密尔顿焦虑量表(HAMA)及汉密尔顿抑郁量表(HAMD)(17项)测量心理状况,将总分值分别大于10和12分判定存在轻中度焦虑、抑郁症状的COPD患者共53例分为艾司西酞普兰组(29例)及对照组(24例),治疗4周后再检测患者COPD的各项指标并用圣乔治呼吸问卷(SGRQ)评价生活质量,应用副反应量表(TESS)记录药物副反应。结果①在53例COPD患者中有抑郁症状20例(37.74%),焦虑症状22例(41.51%),抑郁及焦虑症状并存11例(20.75%);②30例男性COPD患者中表现抑郁症状为40.0%(12/30),焦虑症状为43.3%(13/30);23例女性COPD患者中有抑郁症状34.8%(8/23),焦虑症状为39.1%(9/23),两性间差异无统计学意义(P>0.05);③COPD患者治疗前后HAMA及HAMD评分比较:服用艾司西酞普兰治疗前后各阶段的HAMA、HAMD总分下降与治疗前有显著性差异(P<0.05)。FEV1占预计值及FEV1/FVC(%)均有明显改善(P<0.05),生活质量各评分与对照组比较,差异有显著性意义(P<0.05)。结论艾司西酞普兰能改善COPD患者的焦虑及抑郁症状,治疗期间不良反应较少,能明显提高患者的生活质量。
Objective To study the efficacy and safety of escitalopram in the treatment of patients with chronic obstructive pulmonary disease (COPD) and to evaluate the quality of life before and after treatment. Methods Hamilton status anxiety scale (HAMA) and Hamilton depression scale (HAMD) (17 items) were used to measure the psychological status. A total of 53 patients with mild to moderate anxiety and depressive symptoms were enrolled in the study. The patients were divided into escitalopram group (n = 29) and control group (n = 24). After 4 weeks of treatment, the indexes of COPD were measured and the quality of life was evaluated by St. George’s Respiratory Questionnaire (SGRQ) TESS) recorded drug side effects. Results ① There were 20 cases (37.74%) of depression, 22 cases (41.51%) of anxiety symptoms and 11 cases (20.75%) of depression and anxiety symptoms in 53 COPD patients. ② The depressive symptom of 30 male COPD patients was 40.0 (12/30), 43.3% (13/30) of anxiety; 34.8% (8/23) of depression and 39.1% (9/23) anxiety were found in 23 women with COPD, the difference between the two sexes was no (P> 0.05). ③Comparison of HAMA and HAMD scores before and after treatment of patients with COPD: The decline of HAMA and HAMD score before and after taking Escitalopram was significantly different from that before treatment (P <0.05). FEV1 and FEV1 / FVC (%) were significantly improved (P <0.05). The quality of life scores were significantly different from the control group (P <0.05). Conclusion Escitalopram can improve the symptoms of anxiety and depression in patients with COPD, less adverse reactions during treatment, can significantly improve the quality of life of patients.